Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Forbion
BioCentury | Mar 15, 2025
Editor's Commentary
The NewCo model spurs debate, but it’s about more than money — a Perspective
Expanding the dealmaker’s toolkit to bring Asian innovation to the West
BioCentury | Mar 4, 2025
Management Tracks
Head of R&D Robert Lenz to leave Neumora
Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more
BioCentury | Mar 3, 2025
Deals
The dealmaking at the heart of the NewCo boom
Formed with Hummingbird assets, $187M, Callio brings trend to Singapore
BioCentury | Feb 19, 2025
Management Tracks
Mehta named CMO, Greenberg CBO at Nura Bio
Plus: Shawnte Mitchell joins Olema as chief legal and updates from Loqus23, Pheast, Crafton, Eupraxia and more
BioCentury | Feb 1, 2025
Finance
Investors with deep China roots lead NewCo surge, inspiring Western VCs
Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global
BioCentury | Jan 31, 2025
Finance
Versant, Orbimed lead $65M launch of GIP-focused start-up Helicore
In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund
BioCentury | Jan 15, 2025
Management Tracks
Auspitz becomes managing partner at Curie.bio
Plus: Amphista names Paul Medeiro CBO, and updates from Apellis, Forbion, Eqt, Egle, Spero, Molecular Templates and more
BioCentury | Jan 11, 2025
Finance
Pre-JPM venture bonanza
Fourteen companies announce series A rounds ahead of conference, six with over $100 million
BioCentury | Dec 13, 2024
Editor's Commentary
VC fundraising in a post-‘supercycle’ era: a Perspective
Some firms are no longer making their latest funds their largest; others may follow
BioCentury | Dec 13, 2024
Finance
Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
Items per page:
1 - 10 of 344